Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | RORC | P51449 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.50 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15393387 | 0.98 | NPC1 (0.57) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL18938835 | 0.97 | NPC1 (0.63) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL15393495 | 0.94 | POLB (0.54) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL16699922 | 0.94 | NPC1 (0.62) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL16700835 | 0.90 | TP53 (0.61) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL16700892 | 0.89 | TP53 (0.59) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL16700048 | 0.86 | RORC (0.55) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL16700902 | 0.86 | RAB9A (0.58) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL16699565 | 0.84 | RAB9A (0.59) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL16701115 | 0.83 | RAB9A (0.57) | NPC1SMN1; SMN2RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951033-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2018-04-24 | — | — | US | disclosed |
| US-9951033-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2018-04-24 | — | — | US | disclosed |
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2017-06-08 | — | — | US | disclosed |
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2017-06-08 | — | — | US | disclosed |
| US-9585880-B2 | Cyclic amino compounds for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2017-03-07 | — | — | US | disclosed |
| US-9556111-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2017-01-31 | — | — | US | disclosed |
| US-9556111-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2017-01-31 | — | — | US | disclosed |
| US-20150141456-A1 | CYCLIC AMINO COMPOUNDS FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2015-05-21 | — | — | US | disclosed |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2015-05-14 | — | — | US | disclosed |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | NPC1 1181/4885SMN1; SMN2 2862/4885RAB9A 1672/4885 |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | NPC1 1465/4885SMN1; SMN2 3065/4885RAB9A 1933/4885 |
| US-20150141456-A1 | CYCLIC AMINO COMPOUNDS FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, AKAP8L | NPC1 2105/4885SMN1; SMN2 3721/4885RAB9A 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.